Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Maternal terbinafine use does not affect foetal, pregnancy outcomes

Elaine Soliven
27 Mar 2020

Exposure to oral or topical terbinafine during pregnancy does not increase the risk of major malformations and spontaneous abortion, according to a recent study.

“While terbinafine is a commonly used effective antifungal agent and generally well-tolerated [treatment] in the non-pregnant population, limited data exist on the foetal safety of use in pregnancy,” said the researchers.

“This nationwide cohort study found no increased risk of major malformations or spontaneous abortion among pregnancies exposed to oral or topical terbinafine. These results suggest that terbinafine can be used relatively safely in both oral and topical formulations during pregnancy,” they said.

Using data from the Denmark Medical Birth Registry and National Patient Registry between 1997 and 2016, researchers identified pregnancies exposed to oral terbinafine (n=891, mean age 30.4 years) and topical terbinafine (n=3,174, mean age 29.5 years) and matched them with 40,650 nonexposed pregnancies. Participants were divided into three comparison groups: group A (oral terbinafine exposed [n=522] vs unexposed [n=5,220]), group B (topical terbinafine exposed [n=1,476] vs unexposed [n=14,760]), and group C (oral vs topical terbinafine exposed [n=510 in each group]). [JAMA Dermatol 2020;doi:10.1001/jamadermatol.2020.0142]

The prevalence of major malformations was comparable among infants born to mothers who were exposed and unexposed to oral or topical terbinafine in all groups (group A: 3.8 percent vs 3.8 percent; prevalence odds ratio [OR], 1.01; group B: 3.6 percent vs 3.3 percent; prevalence OR, 1.08; and group C: 3.9 percent vs 3.3 percent; prevalence OR, 1.18).

Similarly, the risk of spontaneous abortion did not differ between pregnancies exposed and unexposed to oral or topical terbinafine (group A: 10.4 percent vs 10.3 percent; hazard ratio [HR], 1.06; group B: 5.2 percent vs 5.1 percent; HR, 1.04; and group C: 10.7 percent vs 9.6 percent; HR, 1.19).

In a sensitivity analysis, the researchers found no statistically significant association between oral terbinafine use and the risk of major malformations and spontaneous abortion.

“Oral terbinafine exposure in pregnancy was not associated with an increased risk of major malformations compared with unexposed pregnancies as well as compared with pregnancies exposed to topical terbinafine,” the researchers said. “Although our results may provide reassurance for pregnancies exposed to oral terbinafine … we cannot exclude a potential increased risk of a specific malformation … [These findings] should [also] be confirmed in other populations.”

“According to current guidelines, topical terbinafine can be safely used during pregnancy because of limited systemic absorption,” noted the researchers. “[T]o our knowledge, this study provides the first data from real-world routine clinical practice and reports no increased risk of major malformation and spontaneous abortion with topical terbinafine use in pregnancy compared with unexposed pregnancies.”
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.